Bank of New York Mellon Corp Has $39.77 Million Stake in Halyard Health, Inc. (HYH)

Bank of New York Mellon Corp trimmed its stake in Halyard Health, Inc. (NYSE:HYH) by 0.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 883,110 shares of the medical instruments supplier’s stock after selling 2,128 shares during the period. Bank of New York Mellon Corp owned approximately 1.89% of Halyard Health worth $39,766,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of HYH. Riverhead Capital Management LLC raised its holdings in shares of Halyard Health by 88.1% in the second quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock worth $126,000 after buying an additional 1,497 shares during the period. LS Investment Advisors LLC raised its holdings in shares of Halyard Health by 16.1% in the second quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock worth $158,000 after buying an additional 556 shares during the period. Jarislowsky Fraser Ltd purchased a new stake in shares of Halyard Health in the third quarter worth approximately $200,000. Quotient Investors LLC purchased a new stake in shares of Halyard Health in the third quarter worth approximately $203,000. Finally, Victory Capital Management Inc. raised its holdings in shares of Halyard Health by 17.7% in the second quarter. Victory Capital Management Inc. now owns 4,732 shares of the medical instruments supplier’s stock worth $186,000 after buying an additional 711 shares during the period. 90.31% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on HYH shares. Zacks Investment Research downgraded Halyard Health from a “buy” rating to a “sell” rating in a report on Wednesday, October 4th. BidaskClub upgraded Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. ValuEngine upgraded Halyard Health from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. KeyCorp restated a “hold” rating on shares of Halyard Health in a report on Tuesday, October 17th. Finally, TheStreet downgraded Halyard Health from a “b-” rating to a “c+” rating in a report on Monday, October 30th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $46.25.

Halyard Health, Inc. (NYSE HYH) traded up $0.26 on Thursday, reaching $47.67. The company’s stock had a trading volume of 214,600 shares, compared to its average volume of 346,681. The stock has a market cap of $2,220.52, a P/E ratio of 22.68, a P/E/G ratio of 2.56 and a beta of 1.77. Halyard Health, Inc. has a one year low of $35.24 and a one year high of $50.99. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.19.

Halyard Health (NYSE:HYH) last released its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, topping the consensus estimate of $0.47 by $0.13. The company had revenue of $401.40 million for the quarter, compared to the consensus estimate of $394.54 million. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. Halyard Health’s quarterly revenue was up 1.0% on a year-over-year basis. During the same period last year, the business posted $0.48 EPS. equities analysts anticipate that Halyard Health, Inc. will post 2.08 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.chaffeybreeze.com/2017/12/07/bank-of-new-york-mellon-corp-has-39-77-million-stake-in-halyard-health-inc-hyh.html.

Halyard Health Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Institutional Ownership by Quarter for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply